3Q EARNINGS: Sanofi underwhelms but believes the worst is over
This article was originally published in Scrip
Executive Summary
Sanofi may not quite be cheering its underwhelming third-quarter results, but there is a definite sense that the company is relieved by the lack of drama after its Q2 results fireworks. Amid figures that show nominal sales growth and disappointing EPS, CEO Christopher Viehbacher emphasized that the worst was over for Sanofi, with the main impact of the patent cliff now behind the pharma giant.